MENU

Why Neuren Pharmaceuticals Ltd (ASX:NEU) shares have been smashed today

One of the worst performers on the Australian share market on Tuesday has been the Neuren Pharmaceuticals Ltd (ASX: NEU) share price.

The shares of the biopharmaceutical company developing therapies for brain injury, neurodevelopmental and neurodegenerative disorders are down a massive 44% to $1.50 in early afternoon trade.

What happened?

This morning Neuren Pharmaceuticals announced that it has entered into an exclusive North American license agreement with ACADIA Pharmaceuticals for the development and commercialisation of trofinetide for Rett syndrome and other indications.

According to the release, ACADIA plans to initiate a Phase 3 study of trofinetide for the treatment of Rett syndrome in the second half of 2019.

Neuren retains all rights to trofinetide outside of North America and will receive an upfront fee of US$10 million plus potential milestones of up to US$455 million and tiered, escalating, double-digit percentage royalties on net sales of trofinetide.

So why are Neuren Pharmaceuticals’ shares being smashed today?

Whilst this deal has the potential to generate significant revenues in the future for the company, I suspect that the market is a little underwhelmed by the upfront payment received and perhaps the company that it has signed the deal with.

Management believes ACADIA is more than capable of developing this novel treatment for Rett syndrome patients, but it isn’t a well-known pharmaceutical company that many had hoped Neuren would have teamed up with.

Should you buy the dip?

This selloff could arguably make Neuren a bargain buy if trofinetide is a success in the North American market. But there is still a long road ahead and success is far from guaranteed.

In light of this, I would hold off an investment for the time being and look at others that are already generating sizeable revenues such as CSL Limited (ASX: CSL) and Mayne Pharma Group Ltd (ASX: MYX).

The ASX small cap up 285% with no sign of stopping...

One Australian company has developed a state of the art device that's revolutionizing hospitals all over the world. Even better, this device is so profitable that the company rakes in 90% margins. That's a lot of cash. So no wonder the stock's up 285% since 2008 – with no signs of stopping...

To discover the name and code, simply click the link below. You'll discover our expert's #1 medical technology pick... and you can decide for yourself whether to get invested today.

Click here to claim your free report.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.